Literature DB >> 15146427

An increased transforming growth factor beta receptor type I:type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor beta receptor type II in scleroderma.

Jaspreet Pannu1, Elizabeth Gore-Hyer, Masayoshi Yamanaka, Edwin A Smith, Semyon Rubinchik, Jian-Yun Dong, Stefania Jablonska, Maria Blaszczyk, Maria Trojanowska.   

Abstract

OBJECTIVE: Aberrant transforming growth factor beta (TGFbeta) signaling has been implicated in the pathogenesis of scleroderma (systemic sclerosis [SSc]), but the contribution of specific components in this pathway to SSc fibroblast phenotype remains unclear. This study was undertaken to delineate the role of TGFbeta receptor type I (TGFbetaRI) and TGFbetaRII in collagen overexpression by SSc fibroblasts.
METHODS: Primary dermal fibroblasts from SSc patients and healthy adults were studied (n = 10 matched pairs). Adenoviral vectors were generated for TGFbetaRI (AdTGFbetaRI), TGFbetaRII (AdTGFbetaRII), and kinase-deficient TGFbetaRII (AdDeltakRII). TGFbetaRI basal protein levels were analyzed by (35)S-methionine labeling/immunoprecipitation and immunohistochemistry. Type I collagen and TGFbetaRII basal protein levels were analyzed by Western blot and newly secreted collagen by (3)H-proline incorporation assay.
RESULTS: Analysis of endogenous TGFbetaRI and TGFbetaRII protein levels revealed that SSc TGFbetaRI levels were increased 1.7-fold (P = 0.008; n = 7) compared with levels in healthy controls, while TGFbetaRII levels were decreased by 30% (P = 0.03; n = 7). This increased TGFbetaRI:TGFbetaRII ratio correlated with SSc collagen overexpression. To determine the consequences of altered TGFbetaRI:TGFbetaRII ratio on collagen expression, healthy fibroblasts were transduced with AdTGFbetaRI or AdTGFbetaRII. Forced expression of TGFbetaRI in the range corresponding to elevated SSc TGFbetaRI levels increased basal collagen expression in a dose-dependent manner, while similar TGFbetaRII overexpression had no effect, although transduction of fibroblasts at higher multiplicities of infection led to a marked reduction of basal collagen levels. Blockade of TGFbeta signaling via AdDeltakRII resulted in approximately 50% inhibition of basal collagen levels in healthy fibroblasts and in 5 of 9 SSc cell lines. A subset of SSc fibroblasts (4 of 9 cell lines) was resistant to this treatment. SSc fibroblasts with the highest levels of TGFbetaRI were the least responsive to collagen inhibition via DeltakRII.
CONCLUSION: This study indicates that an increased TGFbetaRI:TGFbetaRII ratio may underlie aberrant TGFbeta signaling in SSc and contribute to elevated basal collagen production, which is insensitive to TGFbeta signaling blockade via DeltakRII.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15146427     DOI: 10.1002/art.20225

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  25 in total

1.  Deconstructing fibrosis research: do pro-fibrotic signals point the way for chronic dermal wound regeneration?

Authors:  Christopher G Elliott; Douglas W Hamilton
Journal:  J Cell Commun Signal       Date:  2011-04-19       Impact factor: 5.782

Review 2.  Pathogenesis of systemic sclerosis-current concept and emerging treatments.

Authors:  Masutaka Furue; Chikage Mitoma; Hiroki Mitoma; Gaku Tsuji; Takahito Chiba; Takeshi Nakahara; Hiroshi Uchi; Takafumi Kadono
Journal:  Immunol Res       Date:  2017-08       Impact factor: 2.829

3.  Endothelial cell-specific activation of transforming growth factor-β signaling in mice induces cutaneous, visceral, and microvascular fibrosis.

Authors:  Peter J Wermuth; Kellan R Carney; Fabian A Mendoza; Sonsoles Piera-Velazquez; Sergio A Jimenez
Journal:  Lab Invest       Date:  2017-03-27       Impact factor: 5.662

4.  Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth.

Authors:  Douglas S Micalizzi; Chu-An Wang; Susan M Farabaugh; William P Schiemann; Heide L Ford
Journal:  Cancer Res       Date:  2010-11-05       Impact factor: 12.701

Review 5.  Scleroderma, fibroblasts, signaling, and excessive extracellular matrix.

Authors:  Hironobu Ihn
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

6.  siRNA-targeting transforming growth factor-β type I receptor reduces wound scarring and extracellular matrix deposition of scar tissue.

Authors:  Yi-Wen Wang; Nien-Hsien Liou; Juin-Hong Cherng; Shu-Jen Chang; Kuo-Hsing Ma; Earl Fu; Jiang-Chuan Liu; Niann-Tzyy Dai
Journal:  J Invest Dermatol       Date:  2014-02-13       Impact factor: 8.551

7.  MiR-3606-3p inhibits systemic sclerosis through targeting TGF-β type II receptor.

Authors:  Xiangguang Shi; Qingmei Liu; Na Li; Wenzhen Tu; Ruoyu Luo; Xueqian Mei; Yanyun Ma; Weihong Xu; Haiyan Chu; Shuai Jiang; Zhimin Du; Han Zhao; Liang Zhao; Li Jin; Wenyu Wu; Jiucun Wang
Journal:  Cell Cycle       Date:  2018-09-17       Impact factor: 4.534

8.  A large multicentre analysis of CTGF -945 promoter polymorphism does not confirm association with systemic sclerosis susceptibility or phenotype.

Authors:  B Rueda; C Simeon; R Hesselstrand; A Herrick; J Worthington; N Ortego-Centeno; G Riemekasten; V Fonollosa; M C Vonk; F H J van den Hoogen; J Sanchez-Román; M A Aguirre-Zamorano; R García-Portales; A Pros; M T Camps; M A Gonzalez-Gay; M F Gonzalez-Escribano; M J Coenen; N Lambert; J L Nelson; T R D J Radstake; J Martin
Journal:  Ann Rheum Dis       Date:  2008-12-03       Impact factor: 19.103

9.  Towards an anti-fibrotic therapy for scleroderma: targeting myofibroblast differentiation and recruitment.

Authors:  Andrew Leask
Journal:  Fibrogenesis Tissue Repair       Date:  2010-05-27

10.  Established neointimal hyperplasia in vein grafts expands via TGF-beta-mediated progressive fibrosis.

Authors:  Zhihua Jiang; Ming Tao; Kerri A Omalley; Danlu Wang; C Keith Ozaki; Scott A Berceli
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-07-17       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.